Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PLUR
PLUR logo

PLUR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Pluri Inc (PLUR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.330
1 Day change
9.18%
52 Week Range
7.130
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Pluri Inc (PLUR) is not a strong buy at this moment for a beginner investor with a long-term horizon. The technical indicators are bearish, there are no significant positive catalysts, and the financial performance shows improvement in some areas but remains weak overall. Given the lack of strong trading signals and no recent news or influential figure activity, holding off on investing in PLUR is recommended for now.

Technical Analysis

The technical indicators are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 30.653, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 3.358, with key support at 3.144 and resistance at 3.572.

Positive Catalysts

  • Revenue increased by 7.03% YoY, and net income improved significantly (up 121.35% YoY). EPS also improved by 33.96% YoY.

Neutral/Negative Catalysts

  • Gross margin dropped significantly by -27.62% YoY. Technical indicators are bearish, and there is no recent news or significant trading activity from insiders, hedge funds, or Congress.

Financial Performance

In Q2 2026, revenue increased to $198,000 (up 7.03% YoY), net income improved to -$6,543,000 (up 121.35% YoY), and EPS improved to -0.71 (up 33.96% YoY). However, gross margin declined significantly to 43.43% (down -27.62% YoY), indicating potential operational challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast PLUR stock price to rise
Analyst Rating
0
Wall Street analysts forecast PLUR stock price to rise
Buy
Hold
Sell
0
Current: 3.050
sliders
Low
0
Averages
0
High
0
0
Current: 3.050
sliders
Low
0
Averages
0
High
0
Alliance Global Partners
Matthew Venezia
initiated
$12
AI Analysis
2025-06-02
Reason
Alliance Global Partners
Matthew Venezia
Price Target
$12
AI Analysis
2025-06-02
initiated
Reason
Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri with a Buy rating and $12 price target. The company has transitioned from a clinical-stage cell therapy biotech with some novel bioreactor technology to a diversified biotech applying its "differentiated" bioreactor technology in multiple fields, the analyst tells investors in a research note. The firm says Pluri's bioreactor system which solves many issues with current bioreactors related to scale up and production of cell-based products.

People Also Watch